Ellipses' next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ellipses-Pharma

More Like This

PR Newswire associated0

Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Ellipses In-Licenses First-in-Class B7H3 Antibody Drug Conjugate From China

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023